In a recent securities filing, Inotiv, Inc., an Indiana-based contract research organization that provides drug testing services and supplies, disclosed that the Securities and Exchange Commission decided to close an investigation into the company regarding possible violations of the Foreign Corrupt Practices Act.
According to Form 8K filed by Inotiv, the company received a voluntary request for information from the SEC on May 23, 2023, that sought information dating back to December 1, 2017, regarding “the importation of non-human primates from Asia” by Inotiv, Envigo Global Services, Inc., and Orient BioResource Center, Inc. and whether those “importation practices” complied with the FCPA. Inotiv also stated that, in March 2024, it had received a formal order of investigation dated January 9, 2024 and that the company had received supplemental document requests from the SEC on April 12, 2024. The Form 8K then stated that on June 2, 2025, Inotiv’s external counsel had been notified by the SEC that the Division of Enforcement had concluded its investigation and did not intend to pursue an enforcement action against Inotiv.